Celcuity, Inc. is a United States-based early stage biotechnology company. The Company develops tests that functionally analyze diseased live cells. The Company has developed CELx Pathway Profile technology, which combines advancements in primary tissue research with a method of measuring a targeted therapy's functional pathway effect on live and diseased patient cells. The Company offers functional cellular analysis platform that assesses the functionality of the disease-related signaling pathways of patient's diseased cells ex vivo and determines whether a drug therapy has the effect on diseased cells. The Company's CELx test is designed to determine whether a pathway is functional to therapeutic intervention without regard to the exact mechanism a patient's tumor may have developed to resist the therapeutic effect. The Company’s diagnostic approach helps to identify cancer subtypes.